Equities

Torii Pharmaceutical Co Ltd

Torii Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)24.57
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jan 21 2022.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Torii Pharmaceutical Co Ltd grew revenues 11.74% from 48.90bn to 54.64bn while net income improved 4.46% from 3.94bn to 4.12bn.
Gross margin44.46%
Net profit margin8.97%
Operating margin10.93%
Return on assets3.96%
Return on equity4.42%
Return on investment4.39%
More ▼

Cash flow in JPYView more

In 2023, cash reserves at Torii Pharmaceutical Co Ltd fell by 10.74bn. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 3.12bn. In addition the company used 3.78bn on investing activities and also paid 3.84bn in financing cash flows.
Cash flow per share202.68
Price/Cash flow per share21.59
Book value per share4,271.84
Tangible book value per share4,259.53
More ▼

Balance sheet in JPYView more

Torii Pharmaceutical Co Ltd uses little or no debt in its capital structure.
Current ratio6.14
Quick ratio5.19
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)2.33%
Div growth rate (5 year)20.11%
Payout ratio (TTM)69.24%
EPS growth(5 years)28.71
EPS (TTM) vs
TTM 1 year ago
52.63
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.